Compare ENTX & SCWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | SCWO |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.2M | 42.3M |
| IPO Year | 2015 | 2022 |
| Metric | ENTX | SCWO |
|---|---|---|
| Price | $1.22 | $2.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 57.3K | ★ 67.6K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $42,000.00 | ★ $215,037.00 |
| Revenue This Year | N/A | $25,798.80 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.16 |
| 52 Week High | $3.22 | $3.60 |
| Indicator | ENTX | SCWO |
|---|---|---|
| Relative Strength Index (RSI) | 48.48 | 42.13 |
| Support Level | $1.17 | $0.26 |
| Resistance Level | $1.37 | $2.84 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 22.73 | 11.48 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.